Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
General Internal Medicine
•
Hematology
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
Related Questions
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
How does the CLL17 trial presented at ASH 2025 change current practice guidelines?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?
Does the presence of paraneoplastic pemphigus influence your treatment options in CLL?
